



TO REQUEST CONTACT INFORMATION FOR THIS INDIVIDUAL, PLEASE
EMAIL SHAWN TAYLOR KAMINSKI: SKAMINSKI@DIRECTWOMEN.ORG

LORI A. SCHECHTER

EXECUTIVE PROFILE

Recent C-suite executive at a Fortune 10 company with employees in the United States, Canada and Europe. Extensive experience successfully navigating complex, high-profile business and legal matters that require strategic and innovative solutions and effective partnerships, collaboration, and negotiation, often with government entities, to advance business and public policy objectives. Significant experience advising businesses and public boards on risk appetite and reputation enhancement as well as crisis management and preparedness in a highly regulated industry. Over 25 years of management experience leading and building global organizations and teams with over 500 employees in multiple states, countries, and areas of expertise, including government affairs, legal and risk management, marketing and communications, and Board oversight.

EXPERIENCE

MCKESSON CORPORATION (NYSE: MCK) (January 2012 – Present)

A diversified healthcare services company, and the largest pharmaceutical distributor in the U.S., with annual revenues of \$276B in fiscal year 2024 and current market cap of \$71B.

Board & Enterprise Risk Advisor (January 2024-present)

- Advisor to the Board, CEO, and senior management on enterprise risk management issues.
- **EVP, Chief Legal Officer & General Counsel** (June 2014 – December 2023)
- C-Suite leader experienced in strategic planning and support of the company's short- and long-term goals as a healthcare company with offices in North America and certain countries in Europe.
- Managed the legal, public affairs, compliance, quality, corporate governance, and brand, marketing & communications departments comprised of over 500 employees and diverse subject matter experts that manage and mitigate risk while delivering valuable services and solutions to support the company's goals and objectives.
- Facilitated and advised on Board governance, including the Board and director evaluation process, tabletop exercises on cybersecurity and shareholder activism, and meeting agenda setting; led presentations to the Board and various committees, including active participation in the Governance & Sustainability Committee, the Compliance Committee, and the multiple-year special Board committee created to provide strategic oversight on the multitude of pending litigation and investigations involving the distribution of controlled substances, such as opioids.
- Provided advice and direction on business strategy and legal issues to the Chief Executive Officer, the Executive Operating Team, and the Board in critical areas such as government partnership initiatives and contracts, state and federal legislative actions, government regulatory or other investigations, and complex litigation and acquisitions.
- Delivered critical guidance on privacy, cyber and data issues, as well as ESG and emerging ESG-backlash issues while championing and supporting the company's long-standing commitment to DEI through best talent and employee experience initiatives.
- Led the company's navigation of the national opioid crisis, addressing the government-entity and private party litigation landscape, complex and novel legal theories, and the reputational microscope from politicians, shareholders, and the public. Turned challenges into opportunities and partnerships with carefully directed government entity settlements and the formation of a private foundation, both focused on critical response efforts to address the epidemic.

- Led the transformation of the company's Impact Report, ensuring that its annual publications set forth the progress of the company's employees, business initiatives, partnerships, and community outreach in *Advancing Health Outcomes for All*, the company's stated purpose.
- Spearheaded the transformation of the company's risk management program and annual risk assessment process, as well as its crisis preparedness plans and protocols for senior executives and the company's Board of Directors.
- Coordinated the company's legal, public affairs, compliance, and communications teams to enable the company's successful partnership with the U.S. government in its role as the sole distributor selected to deliver COVID-19 vaccines and kits nationwide, as well as with its COVID19 distribution roles in Canada and Europe.
- Launched the company's first pro bono and volunteer, as well as an advocacy ambassador program to enhance the dialogue between McKesson and U.S. Congressional offices on issues of importance to the company and its surrounding communities.

SVP, Associate General Counsel (January 2012 - June 2014)

- Led the Legal Department's litigation, investigations, intellectual property, treasury, and employment & benefits teams.
- Advised senior leadership and the Board on significant litigation and investigations, including investigations by the Department of Justice and other federal and state agencies.

MORRISON & FOERSTER (An international law firm) (October 1988 - December 2011)

Partner with Significant Leadership & Management Roles (January 1995 - December 2011)

- Chaired the firm's 500-lawyer global litigation department with litigation teams in multiple US offices and 11 countries across Europe and Asia for four years.
- Served as a member of the firm's Compensation Committee, Executive Leadership team and Board of Directors over six years.
- Represented fortune 500 pharmaceutical, healthcare, insurance and retail companies in complex litigation and investigations, including class actions, and antitrust, privacy, RICO, false claims act and constitutional litigation.

INTERNATIONAL SUPERVISORY BOARD AND U.S. NON-PROFIT BOARD EXPERIENCE

- April 2024-present: Currently serves on the Supervisory Board of Bayer AG, a global company with core competencies in the life science fields of healthcare and agriculture. The Supervisory Board oversees and advises the company's CEO and Board of Management on matters of fundamental importance to the company, including business strategy and implementation.
- 2015-2022: Served on the Supervisory Board of McKesson Europe, overseeing the German based retail and distribution healthcare company McKesson acquired in 2014.
- 2018-present: Serves on the Board of the Foundation for Opioid Response Efforts since its inception in 2018, including as chair of the Governance Committee. Directed the creation of this independent foundation, launched with a \$100MM contribution from McKesson, to identify and recruit experts to create innovative and replicable programs to combat the opioid crisis.
- 2019-present: Serves on the Board of the National Center for Youth Law, a non-profit dedicated to providing policy advocacy, impactful litigation, collaboration, and research to transform existing approaches to education, health, immigration, foster care, and the justice system that have adverse consequences for youth.

LEADERSHIP RECOGNITION

Recognized in 2022 at the Library of Congress with the Legends in the Law Burton Award based on a demonstrated track record of addressing complex matters of national or global significance in a specialized area.

EDUCATION

Cornell University, B.A. 1983, Phi Beta Kappa; Yale Law School, J.D. 1987.